Sankatsing Valérie D V, van Ravesteyn Nicolien T, Heijnsdijk Eveline A M, Looman Caspar W N, van Luijt Paula A, Fracheboud Jacques, den Heeten Gerard J, Broeders Mireille J M, de Koning Harry J
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Dutch Reference Centre for Screening, Nijmegen, The Netherlands.
Int J Cancer. 2017 Aug 15;141(4):671-677. doi: 10.1002/ijc.30754.
Long-term follow-up data on the effects of screening are scarce, and debate exists on the relative contribution of screening versus treatment to breast cancer mortality reduction. Our aim was therefore to assess the long-term effect of screening by age and time of implementation. We obtained data on 69,630 breast cancer deaths between 1980 and 2010 by municipality (N = 431) and age of death (40-79) in the Netherlands. Breast cancer mortality trends were analyzed by defining the municipality-specific calendar year of introduction of screening as Year 0. Additionally, log-linear Poisson regression was used to estimate the turning point in the trend after Year 0, per municipality, and the annual percentage change (APC) before and after this point. Twenty years after introduction of screening breast cancer mortality was reduced by 30% in women aged 55-74 and by 34% in women aged 75-79, compared to Year 0. A similar and significant decrease was present in municipalities that started early (1987-1992) and late (1995-1997) with screening, despite the difference in availability of effective adjuvant treatment. In the age groups 55-74 and 75-79, the turning point in the trend in breast cancer mortality was estimated in Years 2 and 6 after the introduction of screening, respectively, after which mortality decreased significantly by 1.9% and 2.6% annually. These findings show that the implementation of mammography screening in Dutch municipalities is associated with a significant decline in breast cancer mortality in women aged 55-79, irrespective of time of implementation.
关于筛查效果的长期随访数据稀缺,并且在筛查与治疗对降低乳腺癌死亡率的相对贡献方面存在争议。因此,我们的目的是评估按年龄和实施时间进行筛查的长期效果。我们获取了1980年至2010年间荷兰431个市镇、年龄在40 - 79岁之间的69,630例乳腺癌死亡数据。通过将特定市镇引入筛查的历年定义为第0年,分析乳腺癌死亡率趋势。此外,使用对数线性泊松回归来估计每个市镇在第0年后趋势的转折点以及该点前后的年百分比变化(APC)。与第0年相比,引入筛查20年后,55 - 74岁女性的乳腺癌死亡率降低了30%,75 - 79岁女性降低了34%。在早期(1987 - 1992年)和晚期(1995 - 1997年)开始筛查的市镇中,尽管有效辅助治疗的可及性存在差异,但也出现了类似且显著的下降。在55 - 74岁和75 - 79岁年龄组中,乳腺癌死亡率趋势的转折点分别估计在引入筛查后的第2年和第6年,此后死亡率每年分别显著下降1.9%和2.6%。这些发现表明,荷兰市镇实施乳腺钼靶筛查与55 - 79岁女性乳腺癌死亡率的显著下降相关,与实施时间无关。